The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Hanover Media Strategy Limited naming Bernard Durkan .

Filed returns
39
match these filters
Matching filed returns per period 0 1 2 3 5 Jan–Apr 2017: 1 filed returns May–Aug 2017: 2 filed returns Sep–Dec 2017: 3 filed returns Jan–Apr 2018: 1 filed returns May–Aug 2018: 1 filed returns Sep–Dec 2018: 1 filed returns Jan–Apr 2019: 1 filed returns May–Aug 2019: 2 filed returns Sep–Dec 2019: 1 filed returns Jan–Apr 2020: 1 filed returns May–Aug 2020: 3 filed returns Sep–Dec 2020: 2 filed returns Jan–Apr 2021: 4 filed returns May–Aug 2021: 2 filed returns Sep–Dec 2021: 1 filed returns Jan–Apr 2022: 1 filed returns May–Aug 2022: 1 filed returns Sep–Dec 2022: 1 filed returns Jan–Apr 2023: 2 filed returns May–Aug 2023: 2 filed returns Sep–Dec 2023: 2 filed returns Jan–Apr 2024: 2 filed returns May–Aug 2024: 1 filed returns Sep–Dec 2024: 1 filed returns 2017 2018 2019 2020 2021 2022 2023 2024
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
Sep–Dec 2024 Hanover Media Strategy Limited Health Invite to Leinster House briefing on the burden of influenza in Ireland (Public policy or programme) 15 On lobbying.ie
May–Aug 2024 Hanover Media Strategy Limited Health Request for AV room sponsorship - Influenza Briefing (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2024 Hanover Media Strategy Limited Health Invitation to a roundtable discussion on the challenges and pressures posed by influenza on the Irish health system, with a particular focus on the over 65s population. (Public policy or programme) 15 On lobbying.ie
Jan–Apr 2024 Hanover Media Strategy Limited Health Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) 15 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Health Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) 15 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Health Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) 3 On lobbying.ie
May–Aug 2023 Hanover Media Strategy Limited Health Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) 23 On lobbying.ie
May–Aug 2023 Hanover Media Strategy Limited Health Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) 10 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health The landscape for innovative and precision medicines in Ireland. (Public policy or programme) 12 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) 12 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Transport The impact of vehicle supply shortages on the car rental sector (Public policy or programme) 10 On lobbying.ie
May–Aug 2022 Hanover Media Strategy Limited Transport Shared Pre-Budget 2023 submission to inform policy on shared transport, electrification and vehicle supply (Public policy or programme) 29 On lobbying.ie
Jan–Apr 2022 Hanover Media Strategy Limited Health Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) 14 On lobbying.ie
Sep–Dec 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Finance Cost of Motor Insurance Policies in Ireland (Public policy or programme) 1 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 9 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Finance Consumer protection for SMEs whose loans have been sold to unregulated entities (Legislation) 12 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 9 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 14 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Transport Cost of Motor Insurance Policies in Ireland (Public policy or programme) 85 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 16 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 5 On lobbying.ie
Sep–Dec 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 7 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 13 On lobbying.ie
Jan–Apr 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 12 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) 16 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) 16 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 8 On lobbying.ie
May–Aug 2017 Hanover Media Strategy Limited Health Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) 18 On lobbying.ie
May–Aug 2017 Hanover Media Strategy Limited Health Rare Disease Medicines (Public policy or programme) 11 On lobbying.ie
Jan–Apr 2017 Hanover Media Strategy Limited Health Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) 19 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 34 87.2%
Transport 3 7.7%
Finance 2 5.1%